# Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer

> **NCT03122496** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 13 (actual)

## Conditions studied

- Metastatic Anaplastic Thyroid Cancer

## Interventions

- **DRUG:** durvalumab
- **DRUG:** tremelimumab
- **RADIATION:** Stereotactic Body Radiotherapy (SBRT)

## Key facts

- **NCT ID:** NCT03122496
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-25
- **Primary completion:** 2022-06-03
- **Final completion:** 2022-06-03
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2022-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03122496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03122496, "Immunotherapy and Stereotactic Body Radiotherapy (SBRT) for Metastatic Anaplastic Thyroid Cancer". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03122496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*